(RTTNews) - Bioxytran, Inc. (BIXT) announced positive Phase 2 results for its lead candidate ProLectin-M, showing complete elimination of viral load in 100% of participants at Day 7 compared to placebo.
The Phase 2 study enrolled 38 subjects with laboratory-confirmed acute viral infection. Participants were randomized to receive one of three ProLectin-M dose levels or placebo over a seven-day treatment period. Viral shedding was assessed using RT-PCR analysis of nasopharyngeal swabs, with clearance defined as non-detection of viral RNA.
Key findings included:
•Complete viral clearance in all treated subjects by Day 7 versus placebo.
•No viral rebounds observed during the 14-day post-treatment observation period.
•Early clearance observed in some subjects as early as Day 3, with 16 of 38 cleared by Day 5.
The study confirmed earlier Phase 2 results, validating reproducibility of rapid viral clearance and refining dose selection to four tablets per day.
Bioxytran highlighted that ProLectin-M acts as a galectin antagonist, interfering with viral entry at the cell surface. The company plans to advance regulatory discussions to support late-stage clinical development and evaluate ProLectin-M across additional viral indications.
BIXT has traded between $0.03 and $0.22 over the past year. The stock closed yesterday's trading at $0.04, up 6.44%.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
